ProCure Proton Therapy Center Offers Non-Invasive Solution

ProCure Proton Therapy Center reports that Tom Corlett, a retired New Jersey resident, first learned of his brain tumor by accident, when sinus pain drove him to see his doctor. Several tests later, he was shocked to discover that it was not sinus pain but instead a golf-ball-sized meningioma brain tumor sitting right behind his nose.

As the tumor continued growing, Corlett braced himself for surgery, which he thought was the only viable option, although he was terrified of taking this invasive route.

But after more research, Corlett learned about a non-invasive option at ProCure Proton Therapy Center. Proton therapy is a highly advanced form of radiation treatment that, unlike standard radiation, safely and precisely destroys cancer cells while sparing surrounding healthy tissue.

In Corlett’s case, he chose ProCure because it effectively stopped the tumor from growing. “I had no residual effects from the procedure,” Corlett said. “Physically, I feel fine. I’m back to playing golf and chasing the grandkids around.”

Dr. Brian Chon, ProCure Proton Therapy Center Medical Director, said proton therapy’s precision makes it ideal for many types of cancers, including complex cases and recurrent tumors. Proton therapy can help preserve neurocognitive function by limiting doses to the normal, uninvolved brain when compared to X-ray based treatments.

“We are grateful to play a role in Tom’s journey,” Dr. Chon said. “Brain tumors can significantly impact quality of life, and they are sometimes near critical organs. This often makes proton therapy a good option.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”